# Quality Gate Results — Session 2026-03-26-targeted-001

**Session**: 2026-03-26-targeted-001
**Mode**: BLIND (no WebSearch/WebFetch — parametric knowledge only)
**Target**: Mechanobiology (ECM mechanics) x Epigenomics (enhancer regulation)
**Quality Gate Model**: Opus
**Hypotheses Evaluated**: 5 (C2-H6, E1-H4, E1-H3, C2-H7, E1-H5)
**Date**: 2026-03-26

---

## BLIND MODE NOTICE

All claim verification performed using parametric knowledge only. Web-based novelty
verification and per-claim web grounding were **skipped** per holdout validation protocol.
Citations from 2023-2025 are marked UNVERIFIABLE (potentially post-training-cutoff).
No hypothesis receives full PASS because web novelty check was not performed.
All passing hypotheses receive CONDITIONAL_PASS.

---

## Hypothesis 1: C2-H6 — HDAC3-NCoR Eraser Depletion by ECM Stiffness Creates Enhancer Stabilization Independent of Writer Activation

**Composite Score**: 7.4 | **Revised Confidence**: 4/10 | **Groundedness**: 6/10

| Check | Verdict | Evidence |
|-------|---------|----------|
| A->B->C structure | PASS | A: ECM stiffness -> HDAC3 protein downregulation. B: NCoR/SMRT corepressor dysfunction -> failure to decommission active enhancers -> H3K27ac retention. C: Enhancer stabilization at pre-existing active enhancers (diverse motifs, not TEAD-specific). Clear causal chain with distinct mechanistic steps. |
| Mechanism specificity | PASS | Names HDAC3-NCoR/SMRT complex specifically; references DAD domain requirement (Watson Nature 2012); specifies RGFP966 (HDAC3-selective inhibitor), A-485 (EP300 inhibitor), HDAC3 AAV rescue as triple orthogonal dissection. Two parametric claims acknowledged (HDAC3 dominance at enhancers, half-life extension magnitude). Sufficiently detailed for an epigenetics expert to evaluate. |
| Falsifiable prediction | PASS | Three orthogonal predictions: (1) RGFP966 on soft ECM phenocopies eraser-stabilized subset of stiff-ECM H3K27ac, (2) A-485 on stiff ECM eliminates writer-activated but NOT eraser-stabilized H3K27ac, (3) HDAC3 AAV rescue on stiff ECM collapses eraser-stabilized enhancers. Each independently falsifiable. |
| Counter-evidence | PASS | Genuine risks: HDAC1/2 (NuRD) compensation may render HDAC3 loss insufficient (Knutson 2008 liver KO shows partial phenotype); Fu 2024 studied Parkin (non-histone substrate) in chondrocytes, not enhancer H3K27ac specifically; cell-type specificity; HDAC3 downregulation mechanism by stiff ECM unknown. |
| Test protocol | PASS | Chondrocytes/ATDC5 on PDMS (1/50 kPa, 48h). HDAC3 WB + HDAC3 ChIP-seq. H3K27ac ChIP-seq + ATAC-seq. RGFP966, A-485, HDAC3 AAV. Compare TEAD vs non-TEAD motif gained enhancers. All standard methods, executable in ~3 months. |
| Confidence calibration | PASS | 4/10 (revised by Critic from 5/10). Reasoning: individual components established but novel synthesis untested. HDAC1/2 compensation acknowledged. Honest and well-calibrated. |
| Novelty (parametric) | PASS | Mechanoepigenetics field overwhelmingly assumes writer-activation model (YAP->EP300->H3K27ac). Eraser-depletion inversion is genuinely orthogonal. No paper in my knowledge connects ECM stiffness -> HDAC3 loss -> enhancer landscape changes. Critic confirmed: "conceptually orthogonal to all writer-activation models in the field." |
| Groundedness | PASS | 67% (4/6). You Cell 2013 (HDAC3-NCoR enhancers) VERIFIED. Watson Nature 2012 (DAD domain) VERIFIED. Fu 2024 and Xu 2023 UNVERIFIABLE (post-cutoff). Two parametric claims flagged. Score of 6 is calibrated. |
| Language precision | PASS | HDAC3, NCoR/SMRT, DAD domain, RGFP966, H3K27ac, enhancer decommissioning — all standard epigenetics terminology used correctly. |
| Per-claim verification | CONDITIONAL | 2 VERIFIED, 2 UNVERIFIABLE (post-cutoff), 2 PARAMETRIC. See details below. |

### Per-Claim Verification

| # | Claim | Status | Details |
|---|-------|--------|---------|
| 1 | HDAC3 downregulated by ECM stiffening (Fu Bone Research 2024) | UNVERIFIABLE | Post-cutoff. PMID 38789434 format correct. Plausible finding. |
| 2 | HDAC3-NCoR at enhancers removes H3K27ac (You Cell 2013) | VERIFIED | Landmark paper. HDAC3 deacetylates enhancers via NCoR/SMRT. |
| 3 | Global histone acetylation increase on stiff ECM (Xu Materials Today Bio 2023) | UNVERIFIABLE | Post-cutoff. Plausible — acetylation increases on stiff substrates reported. |
| 4 | NCoR-HDAC3 requires DAD domain (Watson Nature 2012) | VERIFIED | Real paper. DAD domain activates HDAC3 catalytic activity. |
| 5 | HDAC3 is dominant H3K27ac eraser at enhancers (parametric) | CORRECTLY FLAGGED | HDAC1/2 compensation is a genuine risk. |
| 6 | H3K27ac half-life extension magnitude (parametric) | CORRECTLY FLAGGED | Not measured. |

**Protein properties**: HDAC3 removes acetyl groups (deacetylase) CORRECT. Class I HDAC CORRECT.
**Directionality**: HDAC3 REMOVES H3K27ac; depletion -> retention CORRECT.
**Compartment**: HDAC3-NCoR at chromatin/nuclear CORRECT.
**Citation hallucinations**: NONE detected.

**VERDICT: CONDITIONAL_PASS**
**Reason:** Genuinely novel eraser-depletion paradigm inversion with zero citation hallucinations, correct molecular properties, best experimental design in the batch. Two post-cutoff citations unverifiable but show no fabrication signatures. HDAC1/2 compensation is the primary biological risk, honestly flagged.

---

## Hypothesis 2: E1-H4 — H3K27ac as 6-12h Temporal Window for TET2-Mediated CpG Demethylation -> DNA Methylation Mechanical Memory

**Composite Score**: 7.2 | **Revised Confidence**: 4/10 | **Groundedness**: 6/10

| Check | Verdict | Evidence |
|-------|---------|----------|
| A->B->C structure | PASS | A: ECM stiffness -> H3K27ac at mechano-responsive enhancers (6-12h window). B: TET2 recruitment -> 5mC oxidation -> 5hmC -> BER -> CpG demethylation at enhancer shores. C: DNA methylation-based mechanical memory (days-weeks) -> epigenetic priming. |
| Mechanism specificity | PASS | TET2 via OGT tethering, 5mC->5hmC->5fC->5caC cascade, TDG-BER completion (24-72h), DNMT1 maintenance in non-cycling cells. Internally consistent timescales. Priming cycling experiment (50->1->50 kPa) with siTET2 is highly specific. |
| Falsifiable prediction | PASS | Five quantitative predictions: RRBS Delta-Methylation >15%, TET2 CUT&RUN >3-fold, 5hmC DIP-seq >2-fold at 12h, A-485 timing dissection, priming >1.5-fold faster re-induction. |
| Counter-evidence | PASS | TET2 at stiffness-gained enhancers entirely parametric; BER rate uncertainty; DNMT1 kinetics depend on cell cycle; TET2 may prefer Phase 1 enhancers. Genuine risks. |
| Test protocol | PASS | PA hydrogels + CUT&Tag + TET2 CUT&RUN + 5hmC DIP-seq + RRBS + siTET1/siTET2 + A-485 timing + cycling experiment + 5-azacytidine control. Introduces entirely new evidence classes. |
| Confidence calibration | PASS | 4/10 with specific reasoning about parametric claims. Well-calibrated. |
| Novelty (parametric) | PASS | TET2 at enhancers established (Vella 2013, Williams 2011) but TET2 under ECM stiffness is novel. "Temporal window handoff" concept is creative. No paper proposes TET2-mediated DNA methylation mechanical memory. |
| Groundedness | PASS | 6/10. TET2 oxidation cascade VERIFIED (textbook). TET at active enhancers VERIFIED. TDG-BER VERIFIED. DNMT1 VERIFIED. H3K27ac half-life VERIFIED. TET2 under stiffness CORRECTLY FLAGGED parametric. |
| Language precision | PASS | TET2, 5hmC, CpG shores, DIP-seq, RRBS, BER, TDG, OGT — all correct. |
| Per-claim verification | CONDITIONAL | 6 VERIFIED, 3 PARAMETRIC. See details below. |

### Per-Claim Verification

| # | Claim | Status | Details |
|---|-------|--------|---------|
| 1 | TET1/TET2 enriched at H3K27ac+ enhancers (Vella eLife 2013, Williams Cell 2011) | VERIFIED | Both real papers. TET enrichment at active regulatory regions established. NOTE: TET2 lacks a CXXC domain (uses IDAX/CXXC4 instead). Minor imprecision in recruitment mechanism, not fabrication. |
| 2 | EP300 and TET2 co-occupy active enhancers | VERIFIED | Supported by ChIP-seq datasets showing TET2 at H3K27ac+ regions. |
| 3 | 5mC->5hmC->5fC->5caC cascade (Tahiliani Science 2009) | VERIFIED | Tahiliani et al. Science 2009: landmark TET enzyme discovery. Textbook biochemistry. |
| 4 | TDG-mediated BER completes demethylation | VERIFIED | TDG excises 5fC/5caC. Established (He Science 2011). |
| 5 | DNMT1 requires hemi-methylated DNA | VERIFIED | Fundamental DNMT1 biology. |
| 6 | H3K27ac half-life ~2-6h | VERIFIED | Consistent with acetylation kinetics literature. |
| 7 | TET2 co-occupancy at stiffness-gained peaks (parametric) | CORRECTLY FLAGGED | General principle grounded; stiffness context parametric. |
| 8 | CpG demethylation rate at enhancer shores (parametric) | CORRECTLY FLAGGED | BER kinetics variable. |
| 9 | DNMT1 kinetics in non-cycling hMSCs (parametric) | CORRECTLY FLAGGED | Cell division rate dependent. |

**Protein properties**: TET2 OXIDIZES 5mC (correct). EP300 ACETYLATES H3K27 (correct). DNMT1 METHYLATES CpG (correct). TDG is a glycosylase (correct).
**Directionality**: TET2 5mC->5hmC (correct). All enzyme directions verified.
**Compartment**: All at chromatin/nuclear (correct).
**Citation hallucinations**: NONE. Minor TET2/CXXC imprecision (TET2 lacks CXXC domain) is not fabrication.
**Quantity check**: 6-12h H3K27ac window consistent with ~2-6h half-life during ongoing writing. 5hmC at 12h plausible. BER 24-72h reasonable. No order-of-magnitude errors.

**VERDICT: CONDITIONAL_PASS**
**Reason:** Novel TET2 handoff mechanism with internally consistent timescales, no citation hallucinations, correct protein properties, and entirely new evidence classes (5hmC DIP-seq, RRBS). Minor TET2/CXXC imprecision is a recruitment detail, not a bridge-critical fabrication. The priming/hysteresis prediction would answer a fundamental question about mechanical memory.

---

## Hypothesis 3: E1-H3 — Sequential Two-Phase Bivalent Enhancer Activation: YAP-EP300 Phase 1 -> UTX/MLL3-COMPASS Phase 2

**Composite Score**: 7.1 | **Revised Confidence**: 5/10 | **Groundedness**: 6/10

| Check | Verdict | Evidence |
|-------|---------|----------|
| A->B->C structure | PASS | A: ECM stiffness -> YAP-TEAD -> EP300 at non-bivalent enhancers (Phase 1, 0-4h). B: EP300-MLL3/4-COMPASS feedforward -> UTX recruited to bivalent enhancers (Phase 2, 12-24h). C: Bivalent-to-active conversion at developmental loci (SNAI1/RUNX2). |
| Mechanism specificity | PASS | Two-phase model with 8-14h gap; UTX vs KDM6B disambiguation; four-arm siRNA (siKDM6A/siKDM6B/combined/NT); A-485 at 0h vs 8h; re-ChIP at SNAI1 distal enhancer; KDM6A CUT&RUN time-course. Exceptionally specific. |
| Falsifiable prediction | PASS | Five quantitative predictions: 8h temporal gap (KS p<0.001), siKDM6A >50% reduction at bivalent loci, KDM6A enrichment at 12-18h not 4h, A-485 timing dissection, re-ChIP same-locus conversion. |
| Counter-evidence | PASS | UTX-COMPASS recruited independently via MLL3/4 PHD->H3K4me1; GSK-J4 hits both paralogs; KDM6B at enhancers uncertain. Genuine, field-informed risks. |
| Test protocol | PASS | hMSCs, PA hydrogels, CUT&Tag + KDM6A CUT&RUN + four-arm siRNA + A-485 timing + re-ChIP + ATAC-seq + RNA-seq. All standard methods. |
| Confidence calibration | PASS | 5/10: temporal gap specific, feedforward PARAMETRIC, UTX at enhancers grounded but stiffness context novel. |
| Novelty (parametric) | PASS | No paper proposes EP300->COMPASS-UTX feedforward under ECM stiffness. Two-phase temporal model with quantified 8-14h gap is novel. Paralog disambiguation in mechanoepigenetics is new. |
| Groundedness | PASS | 6/10. UTX in COMPASS (Agger Nature 2007, Lee Cell 2007) VERIFIED. Dorighi Mol Cell 2017 VERIFIED. CTGF/CYR61 as YAP targets VERIFIED. EP300-BRD4 VERIFIED. Feedforward and temporal gap CORRECTLY FLAGGED parametric. |
| Language precision | PASS | UTX/KDM6A, KDM6B/JMJD3, MLL3/4-COMPASS, bivalent enhancers, CUT&Tag, CUT&RUN, re-ChIP — all correct. |
| Per-claim verification | PASS | 7 VERIFIED, 2 PARAMETRIC. See details below. |

### Per-Claim Verification

| # | Claim | Status | Details |
|---|-------|--------|---------|
| 1 | UTX is canonical enhancer H3K27me3 demethylase (Agger Nature 2007, Lee Cell 2007) | VERIFIED | Both landmark papers. UTX/KDM6A in MLL/COMPASS confirmed. |
| 2 | KDM6B is stress-inducible promoter demethylase (Yu MCB 2025) | VERIFIED (property) | KDM6B/JMJD3 is NF-kB-inducible, acts at promoters. Yu 2025 UNVERIFIABLE (post-cutoff). |
| 3 | EP300-MLL3/4-COMPASS co-occupy enhancers (Dorighi 2017) | VERIFIED | Dorighi et al. Molecular Cell 2017. Real paper. Note: hypothesis sometimes says "Cell 2017" — journal is Mol Cell. Minor formatting issue. |
| 4 | YAP nuclear translocation rapid (Elosegui-Artola ~2017) | VERIFIED | Published ~2016-2017. YAP translocates within minutes-hours on stiff substrates. |
| 5 | EP300-BRD4 interaction (STRING 0.988) | VERIFIED | Well-documented protein complex interaction. |
| 6 | CTGF/CYR61 as canonical YAP-TEAD targets | VERIFIED | Standard, well-replicated finding. |
| 7 | Bivalent enhancers (H3K4me1+/H3K27me3+) at developmental loci | VERIFIED | Demonstrated in Roadmap Epigenomics and many studies. |
| 8 | EP300->COMPASS-UTX feedforward via co-occupancy (parametric) | CORRECTLY FLAGGED | Emerging from Dorighi 2017 but not shown under stiffness. |
| 9 | 8-14h temporal gap prediction (parametric) | CORRECTLY FLAGGED | Novel prediction, not yet measured. |

**Protein properties**: UTX DEMETHYLATES H3K27me3 (JmjC, alpha-KG-dependent) CORRECT. EP300 ACETYLATES H3K27 CORRECT. KDM6B DEMETHYLATES H3K27me3 CORRECT.
**Directionality**: UTX removes H3K27me3 (Phase 2) CORRECT. EP300 adds H3K27ac (Phase 1) CORRECT.
**Compartment**: All at chromatin/enhancers CORRECT.
**Citation hallucinations**: NONE. Journal inconsistency (Dorighi "Cell" vs "Mol Cell") is minor formatting, not fabrication. Yu MCB 2025 unverifiable but KDM6B properties verified independently.

**VERDICT: CONDITIONAL_PASS**
**Reason:** Most mechanistically specific hypothesis with five independently falsifiable predictions, no citation hallucinations, correct protein properties. The four-arm paralog disambiguation experiment is definitive. UTX independent recruitment via MLL3/4 PHD domain is the strongest counter-argument, honestly acknowledged.

---

## Hypothesis 4: C2-H7 — Integrin Force-Induced H3K9me3 Demethylation at Nuclear Interior Enhancers Creates Competence Windows

**Composite Score**: 6.4 | **Revised Confidence**: 3/10 | **Groundedness**: 5/10

| Check | Verdict | Evidence |
|-------|---------|----------|
| A->B->C structure | PASS | A: ECM stiffness -> integrin-transmitted force via LINC complex. B: H3K9me3 demethylation at nuclear interior enhancers -> heterochromatin decompaction. C: Enhancer competence window (accessible, not yet active) -> enables subsequent H3K27ac by YAP-EP300. |
| Mechanism specificity | CONDITIONAL | Names integrin-LINC, KDM4A/JMJD2A as candidate, nuclear interior vs periphery, DamID-seq, two-step model. BUT: KDM4A identity speculative (Sun 2020 did not identify enzyme); cyclic->static force transfer mechanism unspecified. |
| Falsifiable prediction | PASS | Two-step temporal signature (H3K9me3 loss 1-4h before H3K27ac 6-24h); DamID-seq nuclear interior; chaetocin +/- YAP(S127A) dissection; ML324 KDM4A inhibitor. |
| Counter-evidence | PASS | Sun 2020 used cyclic force not static ECM; H3K9me3 enhancers may be permanently silenced; KDM4A speculative; H3K4me1+H3K9me3 may be <2%. Genuine, self-aware risks. |
| Test protocol | PASS | PA hydrogels, CUT&Tag (H3K9me3/H3K27ac/H3K4me1) + ATAC-seq + DamID-seq + chaetocin +/- YAP(S127A) + ML324 + Sun 2020 replication. Includes critical control experiment. |
| Confidence calibration | PASS | 3/10: honest about cyclic vs static uncertainty, speculative KDM4A, borderline groundedness. Well-calibrated for a hypothesis with fundamental unresolved questions. |
| Novelty (parametric) | PASS | Sun 2020 showed force->H3K9me3 at promoters. Extension to enhancers and "competence window" concept are novel. No paper proposes force-induced H3K9me3 demethylation at enhancers or a two-step competence model. |
| Groundedness | CONDITIONAL | 50% (3/6). BORDERLINE. Sun 2020 VERIFIED. Roadmap data VERIFIED. Nuclear interior differential VERIFIED. KDM4A identity SPECULATIVE. 5-15% enhancer fraction PARAMETRIC. Two-step model PARAMETRIC. The cyclic->static transfer gap is the fundamental grounding concern. |
| Language precision | PASS | H3K9me3, KDM4A/JMJD2A, LINC complex, DamID-seq, lamin B1, chaetocin, ML324 — all correct. |
| Per-claim verification | CONDITIONAL | 3 VERIFIED, 3 PARAMETRIC. See details below. |

### Per-Claim Verification

| # | Claim | Status | Details |
|---|-------|--------|---------|
| 1 | Force->H3K9me3 demethylation at nuclear interior (Sun Sci Advances 2020, PMID 32270037) | VERIFIED | Real paper. Force via integrin-LINC reduces H3K9me3 at nuclear interior loci. |
| 2 | Nuclear interior vs periphery differential (Sun 2020) | VERIFIED | Same paper showed differential response by nuclear position. |
| 3 | H3K4me1+H3K9me3 co-occurrence (Roadmap Epigenomics) | VERIFIED | Such regions exist, though relatively rare and cell-type variable. |
| 4 | KDM4A as force-responsive H3K9me3 demethylase (parametric) | CORRECTLY FLAGGED | KDM4A is a real H3K9me3 demethylase but Sun 2020 did not identify it. |
| 5 | 5-15% of enhancers in H3K9me3 domains (parametric) | CORRECTLY FLAGGED | Varies greatly by cell type. Could be <2% or >15%. |
| 6 | Two-step competence model (parametric) | CORRECTLY FLAGGED | Novel conceptual model, not yet demonstrated. |

**Protein properties**: KDM4A demethylates H3K9me2/me3 (JmjC domain) CORRECT. H3K9me3 is repressive CORRECT. LINC transmits force CORRECT.
**Directionality**: Force -> H3K9me3 REMOVAL CORRECT. Chaetocin inhibits HMTs (prevents H3K9me3 ADDITION) CORRECT.
**Compartment**: Integrin (membrane) -> cytoskeleton -> LINC (envelope) -> nuclear interior CORRECT.
**Citation hallucinations**: NONE. Sun 2020 verified with PMID.
**Force magnitude**: Computational validation 120-920 pN >> 5 pN threshold partially addresses force sufficiency. Does NOT resolve cyclic vs static.

**VERDICT: CONDITIONAL_PASS**
**Reason:** Creative competence window concept with genuine experimental precedent (Sun 2020), correct molecular properties, no citation hallucinations. This is a BORDERLINE pass due to: (1) cyclic vs static force transfer is fundamental and unresolved, (2) KDM4A identity speculative, (3) 50% groundedness is minimum acceptable. Passes because: Sun 2020 provides real grounding, test protocol includes Sun 2020 replication control, force magnitude calculations support sufficiency, and the two-step concept has independent value. Lowest-confidence CONDITIONAL_PASS.

---

## Hypothesis 5: E1-H5 — Dual YAP-TEAD + MRTF-SRF Programs in CTCF-Permitted Loop Domains

**Composite Score**: 6.3 | **Revised Confidence**: 3/10 | **Groundedness**: 5/10

| Check | Verdict | Evidence |
|-------|---------|----------|
| A->B->C structure | PASS | A: ECM stiffness -> two independent H3K27ac programs (YAP-TEAD at CTGF/CYR61, MRTF-SRF at ACTA2/VCL). B: Each program recruits NIPBL-cohesin within pre-established CTCF-anchored domains. C: Two non-overlapping enhancer-promoter contact networks detectable by H3K27ac HiChIP. |
| Mechanism specificity | PASS | Two populations by motif (TEAD vs CArG-box), specific gene loci, CTCF-permitted framing, >70% overlap with constitutive CTCF sites, NIPBL as enabler, verteporfin vs C3-transferase dissection, <20% overlap prediction. |
| Falsifiable prediction | PASS | Five predictions: dual-network HiChIP (>3-fold enrichment each), >70% CTCF-anchored, verteporfin/C3-transferase independent sensitivity, siNIPBL reduces both without CTCF shifts, JQ1 selective for mechano-enhancers. |
| Counter-evidence | PASS | HiChIP technically demanding; empirical survey limits mechanistic impact; mechanism is relatively obvious (Kagey 2010 + Dupont 2011); TADs stable under perturbation (Rao 2017). |
| Test protocol | PASS | MCF10A on PA hydrogels, H3K27ac HiChIP + ChIP-seq + CTCF ChIP-seq + NIPBL CUT&RUN + perturbation panel + 4C-seq + micropatterns. Comprehensive. |
| Confidence calibration | PASS | 3/10: dual-program distinction PARAMETRIC; HiChIP technically demanding; empirical survey. Appropriately low. |
| Novelty (parametric) | CONDITIONAL | DATA is novel (no HiChIP under stiffness with dual-program resolution). MECHANISM is standard biology (active enhancers -> cohesin -> loops within CTCF domains). Critic noted "a grad student knowing Kagey 2010 + Dupont 2011 could predict this." Novelty is in data generation, not conceptual insight. Dual YAP-TEAD + MRTF-SRF framing adds some novelty. |
| Groundedness | PASS | 5/10. YAP-TEAD targets VERIFIED. MRTF-SRF targets VERIFIED. CArG-box VERIFIED. CTCF loops (Rao 2014) VERIFIED. NIPBL/cohesin (Kagey 2010) VERIFIED. C3-transferase, verteporfin VERIFIED. Dual-program non-overlap PARAMETRIC. CTCF unchanged PARAMETRIC. |
| Language precision | PASS | CTCF, TAD, cohesin, NIPBL, HiChIP, CArG-box, TEAD motif, verteporfin, C3-transferase — all correct. |
| Per-claim verification | PASS | 6 VERIFIED, 2 PARAMETRIC. See details below. |

### Per-Claim Verification

| # | Claim | Status | Details |
|---|-------|--------|---------|
| 1 | MRTF-A sequestered by G-actin (Miralles Cell 2003) | VERIFIED | Landmark paper. G-actin sequesters MRTF-A. |
| 2 | YAP requires ~15-20 kPa (Dupont Nature 2011) | VERIFIED | Landmark paper. YAP/TAZ mechanosensitivity. |
| 3 | CArG-box is MRTF-SRF motif | VERIFIED | CC(A/T)6GG standard motif. |
| 4 | CTCF/cohesin loop architecture (Rao Cell 2014) | VERIFIED | Foundational Hi-C paper. |
| 5 | NIPBL promotes cohesin loading (Kagey Nature 2010) | VERIFIED | Mediator/NIPBL/cohesin at enhancers. |
| 6 | Verteporfin inhibits YAP-TEAD; C3-transferase inhibits RhoA | VERIFIED | Standard pharmacological tools. |
| 7 | <20% overlap between TEAD and CArG targets (parametric) | CORRECTLY FLAGGED | Programs target different genes but threshold is a prediction. |
| 8 | CTCF unchanged under stiffness (parametric) | CORRECTLY FLAGGED | Plausible but not formally verified. |

**Protein properties**: NIPBL promotes cohesin loading CORRECT. CTCF anchors loops CORRECT. SRF+MRTF at CArG-box CORRECT. YAP-TEAD at TEAD motif CORRECT.
**Directionality**: No enzyme directionality issues (topology hypothesis).
**Compartment**: All at chromatin CORRECT.
**Citation hallucinations**: NONE. All citations are verified landmark papers.

**VERDICT: CONDITIONAL_PASS**
**Reason:** Well-constructed empirical survey with strong component grounding and no citation hallucinations. Dual-program HiChIP data would be genuinely novel. Main limitation: mechanism is relatively obvious — novelty is primarily in data generation, not conceptual insight. This is the weakest CONDITIONAL_PASS: lowest composite (6.3), lowest novelty contribution among all passing hypotheses, but passes because all individual claims verify and experimental design is sound.

---

## Summary Table

| Rank | ID | Title | Composite | QG Verdict | Adjusted Confidence | Key Strength | Key Risk |
|------|-----|-------|-----------|-----------|---------------------|-------------|----------|
| 1 | C2-H6 | HDAC3-NCoR Eraser Depletion | 7.4 | CONDITIONAL_PASS | 4/10 | Paradigm inversion; best experimental design | HDAC1/2 compensation; Fu 2024 specificity |
| 2 | E1-H4 | TET2-DNA Methylation Memory | 7.2 | CONDITIONAL_PASS | 4/10 | Novel handoff; new evidence classes | TET2 under stiffness parametric |
| 3 | E1-H3 | Two-Phase UTX-COMPASS | 7.1 | CONDITIONAL_PASS | 5/10 | Most mechanistically specific | Feedforward may not exist |
| 4 | C2-H7 | H3K9me3 Competence Windows | 6.4 | CONDITIONAL_PASS | 3/10 | Creative concept; Sun 2020 anchor | Cyclic vs static force; 50% groundedness |
| 5 | E1-H5 | Dual YAP+MRTF Loops | 6.3 | CONDITIONAL_PASS | 3/10 | Novel data; all citations verified | Limited mechanistic novelty |

**Pass rate**: 5/5 CONDITIONAL_PASS (100%)
**Full PASS**: 0/5 (web verification required)
**FAIL**: 0/5

---

## META-VALIDATION

### 1. Reputation check

| ID | Would I bet my reputation? | Notes |
|----|---------------------------|-------|
| C2-H6 | YES | Eraser-depletion inversion is genuine; all verified claims correct |
| E1-H4 | YES | Mechanism internally consistent; new evidence classes |
| E1-H3 | YES | Temporal model testable; four-arm siRNA definitive |
| C2-H7 | BORDERLINE | Cyclic->static is real concern; passes on Sun 2020 + replication control |
| E1-H5 | YES (with reservation) | Novel data, not novel mechanism |

### 2. Verification thoroughness (BLIND MODE)

- C2-H6: 6 claims (2 VERIFIED, 2 UNVERIFIABLE, 2 PARAMETRIC)
- E1-H4: 9 claims (6 VERIFIED, 3 PARAMETRIC)
- E1-H3: 9 claims (7 VERIFIED, 2 PARAMETRIC)
- C2-H7: 6 claims (3 VERIFIED, 3 PARAMETRIC)
- E1-H5: 8 claims (6 VERIFIED, 2 PARAMETRIC)
- **Total**: 38 individual claim verifications

### 3. UNVERIFIABLE claim assessment

All UNVERIFIABLE claims are post-2023 citations. None exhibit hallucination signatures (invented authors, impossible PMIDs, contradictory findings). All accompanied by verifiable molecular properties.

### 4. Citation audit

| Citation | Status |
|----------|--------|
| You Cell 2013 | VERIFIED |
| Watson Nature 2012 | VERIFIED |
| Agger Nature 2007 | VERIFIED |
| Lee Cell 2007 | VERIFIED |
| Dorighi Mol Cell 2017 | VERIFIED (journal sometimes miscited as "Cell") |
| Williams Cell 2011 | VERIFIED |
| Vella eLife 2013 | VERIFIED |
| Tahiliani Science 2009 | VERIFIED |
| Miralles Cell 2003 | VERIFIED |
| Dupont Nature 2011 | VERIFIED |
| Rao Cell 2014 | VERIFIED |
| Kagey Nature 2010 | VERIFIED |
| Sun Sci Advances 2020 | VERIFIED |
| Fu Bone Research 2024 | UNVERIFIABLE (post-cutoff) |
| Xu Materials Today Bio 2023 | UNVERIFIABLE (post-cutoff) |
| Yu MCB 2025 | UNVERIFIABLE (post-cutoff) |

**Citation hallucinations detected: ZERO**

### 5. Strictness justification

All CONDITIONAL_PASS (no full PASS) because:
- Web novelty verification not performed (BLIND MODE)
- Post-cutoff citations UNVERIFIABLE
- Parametric claims could be wrong upon experimental testing

Considered FAIL for C2-H7 (cyclic->static concern) but passed because:
- Sun 2020 provides genuine experimental precedent
- Test protocol includes Sun 2020 replication as required control
- Nuclear force magnitude calculations support sufficiency
- Two-step competence concept has independent value
- Hypothesis honestly flags cyclic->static as its main risk

### 6. 100% CONDITIONAL_PASS rate assessment

Higher than typical quality gate (expect ~60-70% pass rate). Justified because:
- These are cycle 2 hypotheses that survived TWO rounds of critique and one round of evolution
- The pipeline killed 4 hypotheses before these 5 reached QG (C1-H2, C1-H7, C2-H4, C2-H5)
- The Ranker eliminated 3 more (C2-H1, C2-H2, C2-H3)
- These 5 represent the best from a pool of 14 original hypotheses
- In BLIND MODE without web verification, the most common FAIL reason (NOT NOVEL) cannot be applied
- All remaining hypotheses have honest self-critique, correct molecular properties, and no fabricated claims
